arr_large
arr_mini
arr_sp
arr_down
one
two
three
four
five
six
seven
eight
nine
SCOHIA PHARMA, Inc.
Company
Company
Company information
Board members
Corporate Name and Logo
Business
Business
Business process
Business strategy
Management team
Scientific advisor
Pipeline
Pipeline
Pipeline TOP
Direct renin inhibitor |
SCO-272
Enteropeptidase inhibitor |
SCO-792
GPR40 full agonist |
SCO-267
GLP-1R/GIPR dual agonist |
SCO-094
SSTR5 antagonist |
SCO-240
IP6K inhibitor |
SCO-006
NRF2 activator |
SCO-116
Pipeline TOP
Direct renin inhibitor | SCO-272
Enteropeptidase inhibitor | SCO-792
GPR40 full agonist | SCO-267
GLP-1R/GIPR dual agonist | SCO-094
SSTR5 antagonist | SCO-240
IP6K inhibitor | SCO-006
NRF2 activator | SCO-116
News
News
EN
JP
Contact
News
Business
2019.12.09
SCOHIA initiates a Phase1 study of a GPR40 full agonist (SCO-267)
Back All
Page Top
TOP
News
SCOHIA initiates a Phase1 study of a GPR40 full agonist (SCO-267)
